OLMAT AMH 20

About

OLMAT AMH 20 is a potent triple-combination antihypertensive medication formulated to deliver comprehensive and sustained blood pressure reduction by addressing multiple underlying mechanisms of hypertension. This single-pill regimen typically comprises Olmesartan medoxomil, an angiotensin II receptor blocker (ARB); Amlodipine, a dihydropyridine calcium channel blocker; and Hydrochlorothiazide, a thiazide diuretic. Olmesartan works by blocking the effects of angiotensin II, leading to vasodilation and reduced aldosterone secretion. Amlodipine relaxes vascular smooth muscle by inhibiting calcium ion influx, thereby decreasing peripheral vascular resistance. Hydrochlorothiazide enhances the excretion of sodium and water by the kidneys, reducing fluid volume and cardiac preload. The synergistic interaction of these three agents provides a robust antihypertensive effect, making OLMAT AMH 20 an excellent choice for patients with moderate to severe essential hypertension who require aggressive blood pressure control and have not achieved target blood pressure with dual therapy or monotherapy.

Uses

• Treatment of essential hypertension.
• Management of high blood pressure requiring triple therapy.
• When dual therapy is insufficient to achieve target blood pressure.
• Reduction of cardiovascular risk in hypertensive patients.

Directions For Use

Take orally once daily, preferably at the same time each day, with or without food, as directed by your doctor.

Benefits

• Potent and sustained blood pressure reduction.
• Combines three distinct mechanisms of action.
• Improved patient compliance due to single pill.
• Effective for resistant hypertension.
• Reduces overall cardiovascular burden.
• Provides comprehensive blood pressure control.

Side Effects

• Dizziness
• Headache
• Peripheral edema (Amlodipine)
• Fatigue
• Nausea
• Hypotension
• Hyperkalemia (Olmesartan)
• Hypokalemia (Hydrochlorothiazide)
• Muscle cramps
• Increased urination
• Cough
• Rash

Safety Measures

• Alcohol - Limit alcohol intake as it can enhance the hypotensive effects and increase risk of dizziness.
• Pregnancy - Contraindicated during the second and third trimesters due to risk of fetal harm from Olmesartan.
• Breastfeeding - Not recommended; components may pass into breast milk and potentially harm the infant.
• Liver - Use with caution in patients with severe hepatic impairment; dosage adjustments may be necessary.
• Kidney - Use with caution in patients with severe renal impairment; monitor kidney function and electrolytes closely.
• Lung - Generally safe for use in patients with lung conditions; no specific contraindications related to lung function.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.